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ABSTRACT
Understanding mast cell development is essential due to their critical role in 
regulating immunity and autoimmune diseases. Here, we show how Rho kinases 
(ROCK) regulate mast cell development and can function as therapeutic targets for 
treating allergic diseases. Rock1 deficiency results in delayed maturation of bone 
marrow derived mast cells (BMMCs) in response to IL-3 stimulation and reduced 
growth in response to stem cell factor (SCF) stimulation. Further, integrin-mediated 
adhesion and migration, and IgE-mediated degranulation are all impaired in Rock1-
deficient BMMCs. To understand the mechanism behind altered mast cell development 
in Rock1−/− BMMCs, we analyzed the activation of ROCK and its downstream targets 
including LIM kinase (LIMK). We observed reduced activation of ROCK, LIMK, AKT 
and ERK1/2 in Rock1-deficient BMMCs in response to SCF stimulation. Further, loss 
of either Limk1 or Limk2 also demonstrated altered BMMC maturation and growth; 
combined deletion of both Limk1 and Limk2 resulted in further reduction in BMMC 
maturation and growth. In passive cutaneous anaphylaxis model, deficiency of 
Rock1 or treatment with ROCK inhibitor Fasudil protected mice against IgE-mediated 
challenge. Our results identify ROCK/LIMK pathway as a novel therapeutic target for 
treating allergic diseases involving mast cells.
INTRODUCTION
Mast cells regulate both innate and adaptive immunity 
and are involved in various autoimmune diseases [1–3]. 
KIT and IL-3 receptor signaling plays a critical role in mast 
cell growth and differentiation [4–8]. In addition to KIT and 
IL-3 receptors, mast cells also constitutively express the 
high-affinity receptor for Immunoglobulin E (IgE), FcεRI 
[1, 9]. IgE-mediated mast cell activation causes mast cell 
degranulation leading to release of inflammatory mediators 
causing allergic reaction [1, 9]. Evidence suggests that 
IgE-dependent activation of mast cells is critical for the 
pathophysiological manifestations and mortality associated 
with IgE-dependent anaphylaxis [1, 9]. Further, mast 
cells are also major effector cells of asthma and immune 
responses to parasites [10, 11]. Recent studies show that 
many asthma patients have sensitivity to environmental 
allergens and increased levels of antigen-specific and total 
IgE antibodies in serum [12, 13]. Although involvement 
of mast cells in allergic diseases is well characterized, this 
knowledge has not been translated into new therapeutics in 
part to inadequate understanding of the signaling pathways 
involved in the development of mast cells.
Rho kinases or Rho-associated coiled coil-containing 
protein kinases (ROCK) are protein serine/threonine 
kinases. Two isoforms of ROCK have been described 
which are encoded by two separate genes, Rock1 and 
Rock2 [14]. Rock1 and Rock2 share considerable sequence 
homology at the protein level; close to 65% overall and 
nearly 92% in their kinase domains [14]. Activation 
of ROCK leads to phosphorylation of multiple target 
proteins including LIM kinases (LIMK) [15, 16], myosin 
phosphatase (MYPT1) [17], and myosin light chain 
(MLC) [18], which result in the recruitment of mediators 
of actin polymerization and formation of focal adhesions 
leading to changes in growth, survival and cell motility 
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[19]. LIM kinases (LIMK) are serine/threonine kinases 
containing two N-terminal LIM domains, a PDZ domain 
and a C-terminal kinase domain [20–22]. There are two 
isoforms of LIMK, Limk1 and Limk2 which share 50% 
identity overall in amino acid sequence and 70% homology 
in kinase domain [20–22]. LIMK regulates actin dynamics 
through phosphorylation and inactivation of cofilin, a 
member of the actin depolymerizing factor (ADF) family 
[23, 24]. Although the role of ROCK/LIMK pathway in 
regulating actin dynamics is well known, their role in 
mast cell development and functions is not known. Here, 
we define how ROCK/LIMK pathway regulates mast cell 
development and functions, and identify ROCK inhibitors 
as therapeutic drugs for allergic diseases.
RESULTS 
Deficiency of Rock1 results in impaired early 
maturation of bone marrow derived mast cells 
(BMMC)
To determine the role of ROCK in mast cell 
maturation from its precursors in the bone marrow (BM), 
we utilized BM cells derived from WT and Rock1−/− 
mice. Figure 1A shows deletion of Rock1 and expression 
of Rock2 in Rock1−/− bone marrow derived mast cells 
(BMMC). BM cells from WT and Rock1−/− mice were 
cultured for 4 weeks in the presence of IL-3 and their 
maturation into mast cells was assessed by staining the 
cells for the co-expression of KIT and FcεR1 receptors 
followed by flow cytometric analysis. While WT BM cells 
fully matured into KIT and IgE receptor double positive 
mast cells by three weeks of culture, Rock1-deficient 
BMMCs showed reduced maturation at early time points, 
however their maturation was complete by 4 weeks as 
assessed by the presence of close to 100% KIT and IgE 
receptor double positive cells (Figure 1B). Thus, although 
Rock1−/− BM cells lag behind their WT counter parts with 
respect to the acquisition of KIT and IgE receptor double 
positive BMMCs, their expression is completely attained 
by the end of the 4th week of culture. We next analyzed 
the growth of WT and Rock1−/− BMMC’s in response to 
IL-3 by thymidine incorporation. As seen in Figure 1C, no 
difference in the growth of WT and Rock1−/− BMMCs 
was observed in the presence of IL-3. These results suggest 
that Rock1 may play a minor role in the differentiation of 
BMMCs from its precursors in the BM. 
Rock1 deficient BMMCs show reduced growth in 
response to SCF
We next performed studies to analyze the role of 
Rock1 in KIT receptor mediated growth of BMMCs. 
BMMCs derived from WT and Rock1−/− mice at the end 
of week 1, week 2 and week 3 were starved and cultured 
in the presence or absence of SCF for 48 hours, and 
proliferation was analyzed by thymidine incorporation. 
While WT BMMCs demonstrated a significant increase 
in thymidine incorporation in the presence of SCF relative 
to un-stimulated cells, deficiency of Rock1 resulted in a 
significant loss of SCF-mediated growth (Figure 2A). The 
reduced SCF-mediated growth was noted at the end of week 
1, week 2 and week 3. Since Rock1 deficient cells show 
reduced maturation at early times during the culture period, 
we further assessed if the reduced growth in response to 
SCF is either due to reduced KIT expression or due to a cell 
intrinsic defect as a result of Rock1 deficiency. We sorted 
WT and Rock1−/− BMMCs based on KIT expression 
and measured growth in response to SCF stimulation by 
thymidine incorporation. As seen in Figure 2B, sorted KIT 
positive Rock1−/− BMMCs also showed reduced growth 
in response to SCF suggesting a critical role for Rock1 in 
normal growth of mast cells.
Impaired adhesion and migration of BMMCs 
lacking the expression of Rock1
Cellular adhesion is mediated by the direct ligation 
of integrin extracellular domains to defined sequences 
within the extracellular matrix. To understand the 
physiologic role of Rock1 in integrin-mediated adhesion, 
we performed adhesion assays on fibronectin using 
BMMCs derived from WT and Rock1−/− mice. As seen 
in Figure 3A, deficiency of Rock1 in BMMCs resulted 
in a significant reduction in adhesion of BMMCs to 
fibronectin at different time points tested. Since ROCK 
also regulate integrin-mediated migration, we next 
examined the role of Rock1 in integrin (haptotactic) as 
well as in cytokine-induced (chemotaxis) migration of 
BMMCs. BMMCs deficient in Rock1 showed a significant 
reduction in directional migration on retronectin alone 
and in combination with SCF and retronectin (Figure 3B). 
These results suggest that Rock1 plays a vital role in 
integrin-mediated adhesion and migration of BMMCs. 
Deficiency of Rock1 results in reduced IgE-
induced degranulation of BMMCs
Mast cells become activated when surface receptor-
bound antigen-specific immunoglobulin E (IgE) encounters 
an antigen that the IgE recognizes. This triggers mast-cell 
degranulation leading to the rapid release of inflammatory 
mediators including histamine, proteoglycans, and 
cytokines [9, 25, 26]. To understand the role of Rock1 in 
mast cell functions, we performed degranulation assay in 
response to IgE stimulation using BMMCs derived from 
WT and Rock1−/− mice. As seen in Figure 4A, deficiency 
of Rock1 resulted in a significant reduction in IgE-induced 
degranulation. Ag- and IgE-dependent activation of mast 
cells via aggregation of FcεRI is critical for IgE-dependent 
anaphylaxis. Since we observed reduced mast cell activation 
and degranulation in Rock1−/− BMMCs, we next wanted 
to determine whether Rock1 plays any role in anaphylaxis. 
For this, we used an anaphylaxis mouse model in vivo in 
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which IgE-induced passive cutaneous anaphylaxis (PCA) is 
elicited by injecting mice systemically with IgE antibodies 
24 hours before an intravenous challenge with a specific 
antigen [27]. As seen in Figure 4B, mice injected with IgE 
showed significantly profound allergic reaction compared 
to PBS injected mice (data not shown). Importantly, loss 
of Rock1 resulted in significantly reduced allergic reaction 
compared to control mice (Figure 4B). Consistent with 
these findings, treating the mice with a ROCK inhibitor, 
fasudil, significantly inhibited this process (Figure 4C). 
Taken together these results suggest that Rock1 plays an 
important role in mast cell activation and ROCK inhibitors 
might act as therapeutic targets for treating allergic diseases 
involving mast cells.
Reduced activation of ROCK and its 
downstream targets LIMK, AKT and ERK MAP 
kinase in Rock1−/− BMMCs in response to SCF
To determine the mechanism behind altered mast 
cell development and functions in Rock1−/− BMMCs, 
we analyzed the activation of ROCK and its downstream 
Figure 1: Deficiency of Rock1 results in impaired early maturation of bone marrow derived mast cell (BMMC). 
(A) Expression of ROCK isoforms in WT and Rock1−/− BMMCs. Equal amount of protein lysates from WT and Rock1−/− BMMCs were 
subjected to western blot analysis using a Rock1-specific antibody, Rock2-specific antibody and β-actin antibody as indicated. Expression 
of ROCK isoforms is indicated. (B) Deficiency of Rock1 delays the maturation of BMMCs. LDMNCs from WT and Rock1−/− mice 
were cultured in the presence of IL-3 (10 ng/mL) for 4 weeks. At indicated time points, maturation was analyzed by staining the cells 
with antibodies that recognize KIT and IgE receptor followed by flow cytometry. Shown is dot blot profile from one of three independent 
experiments. (C) Rock1 deficiency have no effect on IL-3 mediated growth of BMMCs. BMMCs from WT and Rock1−/− mice were 
starved for 6 hours in serum- and cytokine-free media and cultured in the presence or absence of IL-3 (10 ng/mL). After 48 hours, 
proliferation was evaluated by [3H] thymidine incorporation. Bars represent the mean [3H] thymidine incorporation in BMMCs (CPM + SD) 
from one representative experiment performed in quadruplicate. Similar results were observed in three independent experiments.
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targets LIMK, PI3Kinase/AKT and ERK MAP kinase 
in WT and Rock1−/− BMMCs. BMMCs from WT and 
Rock1−/− mice were starved and stimulated with SCF for 
5 min and analyzed for the activation of ROCK, LIMK, 
AKT and ERK by Western blotting. ROCK activation was 
determined by analyzing the phosphorylation of myosin 
phosphatase, MYPT1, which is downstream target of 
ROCK. Similarly, LIMK activation was determined by 
analyzing the phosphorylation of its downstream target 
cofilin. As seen in Figure 5, a significant decrease in 
the activation of ROCK, LIMK, AKT and ERK1/2 was 
observed in Rock1−/− BMMCs relative to WT. Thus, 
differential regulation of BMMC growth is likely due 
to differential activation of LIMK, AKT and ERK MAP 
kinase downstream from KIT.
ROCK downstream effector LIMK is involved in 
mast cell differentiation and growth
We next studied the role of LIMK in mast cell 
differentiation and growth to determine whether the 
altered mast cell development and functions in Rock1−/− 
Figure 2: Rock1 deficient cells show altered SCF-mediated growth. (A) Deficiency of Rock1 alters the SCF-mediated growth 
of BMMCs. LDMNCs from WT and Rock1−/− mice were cultured in the presence of IL-3 (10 ng/mL) for 3 weeks. At indicated time 
points, proliferation was evaluated by [3H] thymidine incorporation. BMMCs from WT and Rock1−/− mice were starved for 6 hours in 
serum- and cytokine-free media and cultured in the presence or absence of SCF (50 ng/mL). After 48 hours, proliferation was evaluated 
by [3H] thymidine incorporation. Bars represent the mean [3H] thymidine incorporation in BMMCs (CPM + SD) from one representative 
experiment performed in quadruplicate. Similar results were observed in three independent experiments. *p < 0.05, WT vs. Rock1−/−. 
(B) Reduced growth of KIT positive Rock1 deficient BMMMs. LDMNCs from WT and Rock1−/− mice were cultured in the presence of 
IL-3 (10 ng/mL) for 3 weeks. After 3 weeks, BMMCs were sorted based on KIT expression. KIT positive cells were starved for 6 hours in 
serum- and cytokine-free media and cultured in the presence or absence of SCF (50 ng/mL). After 48 hours, proliferation was evaluated by 
a [3H] thymidine incorporation assay. Bars represent the mean [3H] thymidine incorporation in BMMCs (CPM + SD) from one experiment 
performed in quadruplicate. *p < 0.05, WT vs. Rock1−/−. 
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BMMCs is due to reduced activation of LIMK. To study 
the role of LIMK in mast cell development, we used 
Limk1−/−, Limk2−/− and Limk1/−/−:Limk2−/− mice. We 
first cultured BM cells from WT, Limk1−/−, Limk2−/− 
and Limk1/−/−:Limk2−/− mice in the presence of IL-3 
(10 ng/mL) for 3 weeks and at the end of week 1, week 2 
and week 3 measured mast cell differentiation by analyzing 
the co-expression of KIT and FcεR1 receptors by flow 
cytometry. As seen in Figure 6, BMMCs from Limk1−/−, 
Limk2−/− and Limk1/−/−:Limk2−/− mice show reduced 
maturation at the end of week 2 and week 3 compared to 
WT BMMCs. Mast cell differentiation is further less in 
Limk1/−/−:Limk2−/− BMMCs compared to Limk1−/−or 
Limk2−/− BMMCs. We next analyzed the growth of WT, 
Limk1−/−, Limk2−/− and Limk1/−/−:Limk2−/− BMMCs 
in the presence of SCF. While loss of Limk1 or Limk2 
alone shows significantly reduced growth of BMMCs in 
response to SCF stimulation compared to WT BMMCs, 
combined loss of both Limk1 and Limk2 shows further 
reduction in SCF-mediated growth (Figure 6B). These 
results suggest that LIMK plays a major role in mast cell 
differentiation and growth.
DISCUSSION
Mechanisms involved in the growth, maturation 
and function of bone marrow derived mast cells have 
not been fully characterized. In the current study, we 
have explored the role of ROCK1 and Limk1/2 in the 
maturation, growth and actin based functions in bone 
marrow derived mast cells. Our results show that both 
Rock1 and Rock2 are expressed in bone marrow derived 
mast cells, the expression of Rock2 is not modulated in 
the absence of Rock1 in these cells and the phenotypic 
changes observed in Rock1 deficient mast cells are seen in 
spite of normal Rock2 expression. In the absence of Rock1, 
we observe delayed maturation of mast cells, reduced 
growth in response to cytokine stimulation and impaired 
migration and adhesion on fibronectin via β1 integrin’s and 
defects in degranulation. In a model of passive cutaneous 
Figure 3: Rock1 deficiency impacts integrin-mediated adhesion and migration. (A) BMMC’s from WT or Rock1−/− mice 
(1 × 105) were subjected to an in vitro adhesion assay on retronectin as described in methods. Adhesion was assessed by measuring 
absorbance at 600 nM at indicated times. Shown is pooled data from 4–6 independent experiments performed in triplicates ± SEM. 
*P < 0.05 for WT vs Rock1−/−. (B) BMMC’s from WT or Rock1−/− mice (2.5 × 105) were subjected to an in vitro migration assay on 
retronectin as described in methods. Cell migration was performed either in the presence or absence of SCF (50 ng/mL) and is expressed 
as the average number of cells migrated ± SD. Ten fields were scored from one representative experiment. Similar results were observed in 
4 independent experiments. *P < 0.05, WT vs Rock1−/−. 
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anaphylaxis, we see reduced responses in mice lacking 
Rock1 as well as in mice treated with ROCK inhibitor 
fasudil. These functional changes are associated with 
reduced activation of AKT and ERK MAPKinase as well as 
LIMK, as assessed by the phosphorylation of its substrate 
cofilin. Importantly, deficiency of Limk1, Limk2 or both 
impaired the growth and maturation of bone marrow 
derived mast cells. Thus, Rock1/Limk1/2 pathway plays an 
essential role in regulating diverse functions in mast cells. 
While the role of ROCK in non-hematopoietic cells 
utilizing dominant negative approaches and pan ROCK 
inhibitors has been well described; recent studies utilizing 
isoform specific deletion mutants of ROCK have begun 
to shed some light into how these isoforms contribute 
to blood cell development and functions. To this end, 
a role for Rock1 in inflammatory cell migration using 
Rock1−/− mice has been described [28]. An unanticipated 
role for Rock1 in negatively regulating the recruitment 
Figure 4: ROCK inhibition protects against passive cutaneous anaphylaxis (PCA). (A) Deficiency of Rock1 causes reduced 
mast cell degranulation. BMMC’s from WT or Rock1−/− mice were subjected to an in vitro degranulation assay as described in methods. 
The degree of degranulation was determined by measuring the release of β-hexosaminidase. Shown is percentage degranulation ± SD from 
one representative experiment performed in quadruplicates. Similar results were observed in 4 independent experiments. *P < 0.05, WT vs 
Rock1−/−. (B) WT and Rock1−/− mice were injected intradermally with 20 ng anti-DNP IgE on the left ear, whereas the right ear received 
saline as a control. After 24 hours, mice received 100 μg DNP-BSA containing Evan’s blue dye (1% wt/vol) via tail vein injection. After 
30 minutes, ear punches (8 mm) of both ears were collected and were used for extraction of the Evan’s blue dye followed by measurement 
of absorbance at 620 nm. Data is mean ± SEM from one independent experiment (n = 3 mice in each group). *P < 0.05 WT vs Rock1−/− 
mice. Similar results were observed in two independent experiments. Right panel shows the photographs of ears received anti-DNP IgE. 
(C) WT mice were injected intradermally with 20 ng anti-DNP IgE on the left ear, whereas the right ear received saline as a control. 
After 24 hours, mice were divided into two groups and one group received PBS where as other group received ROCK inhibitor fasudil 
(25 mg/kg body weight). After 30 minutes of drug treatment, mice received 100 μg DNP-BSA containing Evan’s blue dye (1% wt/vol) via 
tail vein injection. After 30 minutes, ear punches (8 mm) of both ears were collected and were used for extraction of the Evan’s blue dye 
followed by measurement of absorbance at 620 nm. Data is Mean ± SEM from one independent experiment (n = 3 mice in each group). 
*P < 0.05 vehicle vs fasudil treated. 
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and migration of primary macrophages and neutrophils 
in vitro and in vivo in the context of whole organism was 
also shown [28]. Specifically, enhanced migration of both 
Rock1 deficient macrophages and neutrophils in response 
to multiple stimuli was documented. The observed 
defects were not attributed to changes in the maturation 
and expression of β1 integrins or to the compensation by 
Rock2. At the biochemical level, Rock1 was shown to 
regulate the intracellular levels of phosphatidylinositol 
(3, 4, 5)-triphosphate/AKT in response to receptor activation 
by regulating the phosphorylation, degradation, stability 
and activity of tumor-suppressor protein phosphatase 
and tensin homolog (PTEN) [28]. Thus, it appears that at 
least in macrophages, Rock1 plays an important role in 
regulating the stability and activity of PTEN. Importantly, 
deregulation of this pathway in Rock1-deficient cells results 
in enhanced recruitment of macrophages in vivo. In the 
context of a different blood lineage, deficiency of Rock1 
in a model of oxidative stress showed rapid and enhanced 
recovery of red blood cells from hematopoietic stem/
progenitor cells in the bone marrow lacking Rock1, in part 
by regulating the expression/phosphorylation of p53 [29]. 
These findings are consistent with the fact that loss of p53 
in p53-deficient mice also results in enhanced erythroid 
cell recovery following an oxidative challenge [30]. Taken 
together, studies described in Rock1-deficient mice, thus far, 
suggest that Rock1 may play an essential role in negatively 
regulating the survival of multiple hematopoietic lineages 
in the context of both inflammatory as well as oxidative 
stress in myeloid and erythroid cells, respectively, in part 
by regulating the activation of tumor-suppressor genes such 
as PTEN and p53. Our current studies in mast cells suggest 
that the mechanism(s) by which Rock1 impacts macrophage 
and erythroid cell functions is not the same as how Rock1 
regulates mast cell development and functions. Our findings 
show that Rock1 is a positive regulator of mast cell functions 
including adhesion, migration and degranulation in part by 
regulating the activation of LIMK. Thus, Rock1 is likely 
to regulate cellular functions based on the presence and 
activation of downstream substrates in specific cell types.
Figure 5: Rock1 regulates KIT mediated signaling in BMMCs. Reduced activation of ROCK, LIMK, AKT and ERK MAP 
kinase in Rock1-deficient BMMCs. WT and Rock1−/− BMMCs were starved overnight in serum- and cytokine-free media and stimulated 
with SCF (100 ng/mL) for 5 min. Equal amount of protein lysates were subjected to western blot analysis using an anti-Rock1, anti-Rock2, 
anti-phospho-MYPT1, anti-β-actin, anti-phospho-AKT, anti-phospho-ERK1/2, anti-total AKT or anti-total ERK1/2 antibodies as indicated. 
Similar findings were observed in 3–4 independent experiments.
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Our biochemical findings suggest that downstream 
from Rock1, LIMK activation as assessed by 
phosphorylation of cofilin is significantly altered in mast 
cells. LIMK is a key regulator of actin cytoskeleton. 
They phosphorylate and inactivate cofilin. Given 
that cofilin plays a prominent role in promoting actin 
depolymerization and that active (unphosphorylated) 
cofilin induces severing of actin filaments and contributes 
to cell migration, cell cycle and differentiation, we 
sought to assess the role of both Limk1 and Limk2 
[24]. We show that both Limk1 and Limk2 play an 
equally important role in regulating the maturation and 
growth of mast cells. Given our findings in a model of 
anaphylaxis and recent studies showing an essential role 
for ROCK in an allergic airway disease model in which 
mast cells contribute significantly [31, 32], targeting 
LIMK using small molecule inhibitors may be a prudent 
therapeutic option.
Figure 6: LIMK plays an important role in BMMC maturation, growth and survival. (A) LDMNCs from WT, Limk1−/−, 
Limk2−/− and Limk1−/−:Limk2−/− mice were cultured in the presence of IL-3 (10 ng/mL) for 3 weeks. At indicated time points, maturation 
was analyzed by staining the cells with antibodies that recognize KIT and IgE receptor followed by flow cytometry. Shown is dot blot 
profile from one of four independent experiments. (B) BMMCs from WT, Limk1−/−, Limk2−/− and Limk1−/−:Limk2−/− mice were starved 
for 6 hours in serum- and cytokine-free media and cultured in the presence or absence of SCF (50 ng/mL). After 48 hours, proliferation 
was evaluated by [3H] thymidine incorporation. Bars represent the mean [3H] thymidine incorporation in BMMCs (CPM + SD) from 
one representative experiment performed in triplicate. Similar results were observed in four independent experiments. *p < 0.05, WT vs. 
Limk1−/− or Limk2−/−, **p < 0.05, Limk1−/− or Limk2−/− vs. Limk1−/−:Limk2−/−. 
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MATERIALS AND METHODS
Cytokines, antibodies and reagents
Recombinant murine interleukin-3 (IL-3) and 
stem cell factor (SCF) were purchased from Pepro Tech, 
(Rocky Hill, NJ). Allophycocyanin (APC)-conjugated KIT 
antibody, Phycoerythrin (PE)-conjugated FcεR1 antibody, 
PE-Annexin V antibody and 7-Amino actinomycin D 
(7-AAD) were purchased from BD Biosciences (San Jose, 
CA). Rabbit anti–Rock1 and anti-Rock2 antibodies were 
purchased from Santa Cruz Biotechnology (Santacruz, 
CA). Rabbit anti-MYPT1 antibody was purchased from 
Upstate (Lake Placid, NY). Rabbit anti-phospho-cofilin, 
anti-phospho-AKT, anti-phospho-ERK, anti-cofilin, anti-
AKT and anti-ERK1/2 antibodies were purchased from 
Cell signaling Technology (Beverly, MA). Retronectin was 
purchased from Takara (Madison, WI). Iscove’s Modified 
Dulbecco’s Medium (IMDM) was purchased from 
Invitrogen (Carlsbad, CA). [3H] Thymidine was purchased 
from PerkinElmer (Boston, MA).
Mice 
Mice deficient in Rock1, Limk1, and Limk2 
have been previously described [33–35]. All mice were 
maintained under specific pathogen-free conditions at the 
Indiana University Laboratory Animal Research Center 
(Indianapolis, IN). All animal procedures were conducted 
in accordance with the Guidelines for the Care and Use of 
Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committees (IACUCs) at Indiana 
University School of Medicine.
Generation of bone marrow derived mast 
(BMMC) cells 
To generate BMMCs, low density bone marrow cells 
(LDBMCs) from WT and various knockout mice were 
cultured in the presence of IL-3 (10 ng/mL) for 3–4 weeks. 
These in vitro generated BMMCs were used to perform 
in vitro functional and biochemical experiments described 
here.
Mast cell maturation 
Maturation of BMMCs from WT and various 
knockout mice was analyzed by examining the expression 
of KIT and IgE receptor using flow cytometry as described 
previously [36]. BMMCs (1 × 106) were blocked with 10% 
rat serum in phosphate buffered saline (PBS) containing 
0.2% bovine serum albumin (BSA) (Sigma, St Louis, MO) 
for 30 min at 4°C. After blocking, cells were incubated 
with 1 µg of anti-APC-KIT and anti-PE-FcεR1 antibodies 
for 30 min at 4°C. Cells were washed to remove unbound 
antibodies with PBS containing 0.2% BSA and analyzed by 
flow cytometry (Becton Dickinson, San Jose, CA). 
Proliferation assay
Proliferation was assessed by conducting a thymidine 
incorporation assay as described previously [37, 38]. Briefly, 
cells were washed and starved in IMDM containing 0.2% 
BSA without serum or growth factors for 6 to 8 hours. Cells 
(5 × 104) were plated in replicates of four in a 96-well plate in 
200 μL complete medium either in the absence or presence 
of the indicated growth factors. The cells were cultured for 
48 hours and subsequently pulsed with 1.0 μCi (0.037 MBq) 
[3H] thymidine (PerkinElmer) for 6 hours and harvested using 
an automated 96-well cell harvester (Brandel). Thymidine 
incorporation was assessed as counts per minute (CPM).
Adhesion on fibronectin
In vitro integrin-mediated adhesion assay was 
conducted as previously described [39]. Briefly, flat-bottom 
96-well polystyrene plates (BD Biosciences) were coated 
with 20 μg/mL retronectin in PBS for 1 hour at 37°C. Wells 
were washed twice with PBS, incubated with 20 mg/mL 
bovine serum albumin (BSA) for 1 hour at 37°C for 
blocking nonspecific sites, and again washed twice with 
PBS. To examine cell adhesion on the coated surface, 
1 × 105 cells were added to each well and incubated at 37°C 
for indicated times. At the end of the incubation, unbound 
cells were removed by aspiration carefully, and wells were 
washed twice with cold PBS. Adherent cells were fixed with 
3.5% formaldehyde and stained with 0.1% crystal violet. 
The stain was eluted with 10% acetic acid, and absorbance 
was determined at 600 nm using a microplate reader 
(Spectramax 250; Molecular Device, Sunnyvale, CA).
Integrin-mediated migration assay
In vitro haptotactic migration assay was conducted 
as previously described [39]. Briefly, the transwell filters 
(8 μM pore filter; Costar, Boston, MA) were coated on 
the underside with 20 μg/mL retronectin (RN) for 2 hours 
at 37°C, and rinsed twice with PBS containing 2% BSA. 
The RN-coated filters were placed in the lower chamber 
containing 500 μL complete medium with or without SCF 
(100 ng/mL). BMMCs (2.5 × 105) were re-suspended 
in 100 μL IMDM and allowed to migrate toward the 
underside of the top chamber. After 4 hours of incubation at 
37°C, non-migrated cells on the upper side of the chamber 
were removed and the migrated cells attached to the bottom 
surface of the membrane were stained with 0.1% crystal 
violet, 0.1 M borate, pH 9.0, and 2% ethanol for 5 minutes 
at room temperature. The numbers of migrated cells per 
membrane were counted in 10 random fields with an 
inverted microscope using X20 objective lens. 
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Mast cell degranulation assay
Mast cell degranulation was analyzed as described 
previously [40]. BMMCs from WT or Rock1−/− mice 
were washed and starved in RPMI containing 0.5% BSA 
for 6 hours and then resuspended in Tyrode buffer (10 mM 
HEPES buffer, pH 7.4, 130 mM NaCI, 5 mM KCI, 1.4 mM 
CaCI
2
, 1 mM MgCI
2
, 5.6 mM glucose, and 0.1% BSA). 
For measuring degranulation in response to IgE, cells were 
sensitized with 10 mg/mL anti-dinitrophenyl (anti-DNP) 
IgE mAb SPE-7 (Sigma-Aldrich) for 1 hour, washed twice 
with 23°C Tyrode buffer, equilibrated in Tyrode buffer to 
37°C for 5 minutes, and then treated for 15 minutes with 
DNP-human serum albumin (Sigma-Aldrich). The degree 
of degranulation was determined by measuring the release 
of β-hexosaminidase.
IgE-mediated passive cutaneous anaphylaxis 
(PCA)
Passive cutaneous anaphylaxis mouse model was 
developed as described previously [27]. WT and Rock1−/− 
mice were sensitized with intradermal injection of 20 ng 
anti-DNP IgE mAb (Sigma-Aldrich) into the left ears, 
whereas the right ears received saline as control. After 
24 hours, mice were challenged by intravenous injection 
of 100 μg DNP-BSA in 200 μL of Evan’s blue dye (1% 
wt/vol; Sigma-Aldrich). After 30 minutes, an 8-mm ear 
punch was collected in 300 μL of formamide and incubated 
at 80°C for 2 hours in water bath. After incubation, the 
extract of Evan’s blue dye was measured by absorbance 
at 620 nm in a spectrophotometer. To test whether Rho 
kinase inhibitor fasudil can be used to treat anaphylaxis, 
we treated WT mice with Rho kinase inhibitor fasudil 30 
minutes before challenging the mice with DNP-BSA. 
Western blotting
Western blotting was performed as described 
previously [37]. Equal amount of protein extracts were 
separated on 4–20% SDS-polyacrylamide gels. After 
electrophoresis, the proteins were transferred onto 
nitrocellulose membranes and nonspecific binding was 
blocked with 5% nonfat dry milk in Tris-buffered saline 
containing 0.1% Tween-20 (TBS-T). Membranes were 
then probed with various antibodies overnight at 4oC 
on a rocker. After incubation, membranes were washed 
with TBS-T and incubated with appropriate horse radish 
peroxidase (HRP)-conjugated secondary antibodies for 
1 hour at room temperature. After washing the membranes 
with TBS-T, the proteins on the membranes were detected 
using SuperSignal West Dura Luminol /Enhancer solution 
(Thermo Fisher Scientific, Rockford, IL) and exposing the 
membranes to X-ray film. 
Statistics 
All graphical data were evaluated by paired Student 
t test, and results were considered significantly different 
with P value < .05. All data are represented as mean + SD 
or SEM as indicated in Figure legends.
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